Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Kidney Neoplasms, Liver N...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on prior ultrasound or cross-sectional imaging-will be imaged. Recruitment will be conducted such that ten patients are included from each anatomic region. The fourth arm will consist of 10 healthy volunteers who will be imaged to allow optimization of imaging parameters. Optimization is is required again due to the use of a different ultrasound system employing a new imaging technique. Parameters such as frame rate, power, depth of imaging, and linear translation rate will be adjusted during this process. The primary objectives of the study are to assess the sensitivity and specificity of Contrast Enhanced Super-Resolution (CESR) imaging in evaluating known lesions in the breast, liver, and kidney. These results will be compared with pathological findings. The secondary objectives are to compare the sensitivity and specificity of CESR imaging with those of traditional B-mode ultrasound in differentiating malignant from benign lesions in these same organs.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: contrast agent perflutren lipid — At the time of imaging, the contrast agent perflutren lipid will be administered, intravenous (IV). All patients will be visually monitored for signs or symptoms of a contrast administration reaction once the drug is administered for a 15-minute period.
  • Device: Ultrasound Imaging — Contrast Enhanced Super Resolution (CESR) imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to CESR imaging for localization.

Primary Outcomes

  • Sensitivity of Contrast Enhanced Super-Resolution (CESR) breast imaging (Biopsy date (Up to 2 months))
  • Specificity of Contrast Enhanced Super-Resolution (CESR) breast imaging (Biopsy date (Up to 2 months))
  • Sensitivity of Contrast Enhanced Super-Resolution (CESR) kidney imaging (Biopsy date (Up to 2 months))
  • Specificity of Contrast Enhanced Super-Resolution (CESR) kidney imaging (Biopsy date (Up to 2 months))
  • Sensitivity of Contrast Enhanced Super-Resolution (CESR) liver imaging (Biopsy date (Up to 2 months))
  • Specificity of Contrast Enhanced Super-Resolution (CESR) liver imaging (Biopsy date (Up to 2 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-04
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Yueh Lee, MD (PRINCIPAL_INVESTIGATOR) - UNC Lineberger Comprehensive Cancer Center
Contact Information
Study Contact:
Desma Jones
(919) 843-9463
desma_jones@med.unc.edu
Markeela Lipscomb
(919) 843-3670
markeela_lipscomb@med.unc.edu
Markeela Lipscomb
919-984-0000
markeela_lipscomb@med.unc.edu
The University of North Carolina
Interventions
  • Drug: contrast agent perflutren lipid — At the time of imaging, the contrast agent perflutren lipid will be administered, intravenous (IV). All patients will be visually monitored for signs or symptoms of a contrast administration reaction once the drug is administered for a 15-minute period.
  • Device: Ultrasound Imaging — Contrast Enhanced Super Resolution (CESR) imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to CESR imaging for localization.
Study Locations (1 sites)
The University of North Carolina, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years old * Patient had a diagnostic ultrasound study performed at University of North Carolina * Scheduled for a biopsy * Lesion visualized on ultrasound * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential Exclusion Criteria: * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity®) * Active cardiac disease including any of the following * Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association) * Unstable angina. * Severe arrhythmia (i.e., ventricular tachycardia, flutter fibrillation; ventricular premature complexes occurring close to the preceding T-wave, multifocal complexes). * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts

MELIORA Data Collection Campaigns

NCT07190066
Recruiting
Conditions Breast Cancer Prevention
Phase NA
Enrollment 300
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To support the development of the MELIORA digital app for the MELIORA main intervention, an initial pilot study (Data Collection Campaign, DCC) is being conducted with the three target participant groups: healthy women at increased risk of developing breast cancer (BC), BC patients, and BC survivors across the four intervention countries (Spain, Greece, Lithuania, Sweden). The planned sample size for each group is 156 healthy women at risk (defined as not meeting recommendations for a healthy lifestyle), 58 BC patients, and 86 BC survivors. Each participant is asked to test and evaluate a preliminary version of the MELIORA app over a 14-day period. The DCC takes place in the early stages of the project, as part of the intervention development phase, to inform the technical refinement and preliminary evaluation of the MELIORA digital app.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Data Collection campaign — Participants will be asked to download the MELIROA app, compatible with iOS and Android, to their smartphones and test it for 14 days. The app will prompt the user to set a weekly goal on physical activity and support daily self-monitoring and step count tracking. Τhe app will also offer culturally adapted educational material through mini-courses, motivational and practical tips and an embedded library of materials relevant to physical activity, healthy diet and alcohol consumption. To boost motivation, it will also include reminders and gamification features like badges and points.

Primary Outcomes

  • Usability (14 days)
  • Relevance, appropriateness and usefulness (14 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-22
Completion: 2025-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Harokopio University
Collaborators: BROSTCANCERFORENINGEN AMAZONA I STOCKHOLMS LAN, FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA, Instituto de Investigacion Sanitaria INCLIVA, LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS, PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJA, SWPS UNIWERSYTET HUMANISTYCZNOSPOLECZNY, EUROPEAN FOOD INFORMATION COUNCIL, ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS, EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS, RISA SICHERHEITSANALYSEN GMBH, BioAssist, EUROPEAN HEALTH MANAGEMENT ASSOCIATION, ETICAS DATA SOCIETY, Karolinska Institutet, PredictBy Research and Consulting, S.L
Principal Investigators:
  • Yannis Manios, Professor (PRINCIPAL_INVESTIGATOR) - Department of Nutrition and Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece
Contact Information
Study Contact:
Yannis Manios, Professor
+30 2109549156
manios@hua.gr
Yannis Manios, Professor
+302109549156
manios@hua.gr
Harokopio University
Gintare Kaliniene
+370868409708
gintare.kaliniene@lsmu.lt
Lietuvos Sveikatos Mokslų Universitetas (Lsmu)
Interventions
  • Other: Data Collection campaign — Participants will be asked to download the MELIROA app, compatible with iOS and Android, to their smartphones and test it for 14 days. The app will prompt the user to set a weekly goal on physical activity and support daily self-monitoring and step count tracking. Τhe app will also offer culturally adapted educational material through mini-courses, motivational and practical tips and an embedded library of materials relevant to physical activity, healthy diet and alcohol consumption. To boost motivation, it will also include reminders and gamification features like badges and points.
Study Locations (7 sites)
Harokopio University, Athens, Greece
Lietuvos Sveikatos Mokslų Universitetas (Lsmu), Kaunas, Lithuania
Pagalbos Onkologiniams Ligoniams Asociacija (Pola L T), Kaunas, Lithuania
Fundación Para El Fomento de La Investigación Sanitaria Y Biomédica de La Comunitat Valenciana (Fisabio), Valencia, Spain
INCLIVA - Instituto de Investigación Sanitaria, Valencia, Spain
Bröstcancerföreningen Amazona I Stockholms Län (Amazona), Stockholm, Sweden
Karolinska Institutet, Stockholm, Sweden
Eligibility Criteria
Inclusion Criteria: * Individuals residing in Greece, Lithuania, Spain or Sweden. * Female adults (i.e. ≥18 years of age). * Ability to understand and complete the outcome measures in one of the participating countries' local languages. * Ability to provide fully informed consent. * Having access to and being able to use a smartphone that supports the project app (i.e., iOS or Android smartphone) * Meeting the criteria for allocation to one of the three following groups: * Healthy women with a calculated Βody Μass Ιndex (BMI) ≥ 25 or not meeting the World Health Organization's recommendations of ≥150 minutes of moderate-to-vigorous physical activity per week. * Women currently undergoing active treatment for breast cancer or awaiting to begin active treatment for breast cancer. * Women survivors of BC having completed active treatment at least six months prior to study enrolment Exclusion Criteria: * Inability to provide fully informed consent. * Inability to understand and communicate in one of the recruitment countries' local languages.
Conditions Obesity & Overweight
Phase PHASE3
Enrollment 825
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a ratio of 1:1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: HDM1005 1 — Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
  • Drug: HDM1005 2 — Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.
  • Drug: Placebo — Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.

Primary Outcomes

  • primary outcome (week 40)
  • Co-primary outcome (week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-14
Completion: 2026-12-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 825 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Principal Investigators:
  • Xiaoying Li (PRINCIPAL_INVESTIGATOR) - Shanghai Zhongshan Hospital
Contact Information
Study Contact:
Hui Qiao
+86 0571-89908523
qiaohui@eastchinapharm.com
Xiaoying Li
+86 021-64041990
Xiaoying_li@Hotmail.com
Zhongshan Hoapital
Interventions
  • Drug: HDM1005 1 — Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.
  • Drug: HDM1005 2 — Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.
  • Drug: Placebo — Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose. The intervention will last for 52 weeks in total.
Study Locations (1 sites)
Zhongshan Hoapital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Male or female, aged ≥18 years at the time of signing informed consent. 2. BMI≥28 kg/m2 or ≥24 kg/m2 and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, pre-diabetes, obstructive sleep apnea, fatty liver, weight-bearing joint pain. 3. A self-reported change in body weight no more than 5% within 90 days before screening. 4. Able to understand the procedures and methods of this study, willing to strictly comply with the clinical trial protocol to complete this trial, and voluntarily sign the informed consent form. Exclusion Criteria: 1. Have type 1 diabetes mellitus (T1DM) or T2DM. 2. Have HbA1c≥6.5% or fasting serum glucose (FSG)≥7.0 mmol/L at Visit 1. 3. Have obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or by other medicine. 4. Use of GLP-1 receptor (GLP-1R) agonists or GLP-1R/GCGR agonists or GIPR/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists within 3 months prior to screening. 5. Use of hypoglycemic drugs within 3 months prior to screening. 6. History of thyroid C-cell carcinoma, multiple endocrine neoplasia (MEN) 2A or 2B or relevant family history. 7. Previous history of acute and chronic pancreatitis, acute gallbladder disease history (except cholecystectomy) history. 8. PHQ questionnaire ≥ 15 points at screening or randomization. 9. Have had a history of moderate to severe depression; Or have a history of severe mental illness in the past. 10. Uncontrolled hypertension prior to screening, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg (stable for 1 month if using antihypertensive drugs). 11. History of malignancy (except cured basal cell carcinoma) in the past 5 years or at the time of screening. 12. History of severe cardiovascular or cerebrovascular diseases within the past six months. 13. History of alcohol and drug abuse at screening. 14. The participant may be allergic to ingredients in the study drug or drugs of the same class. 15. Pregnant or lactating females, males or females of childbearing potential not willing to use contraception throughout the study. 16. The subject has any other factors that may affect the efficacy or safety evaluation of this study, and is not suitable for participation in this study in the opinion of the investigator.
Conditions Breast Cancer-Related Lymphedema, BCRL
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer among women worldwide and lymphedema is one of its most significant complications. Breast cancer-related lymphedema (BCRL) may develop shortly after treatment or even years later, causing physical and psychological burden, functional impairment, and reduced quality of life. Complete decongestive therapy (CDT), which includes manual lymph drainage (MLD), compression, skin care, and exercise, is the standard approach. Intermittent pneumatic compression (IPC) has been proposed as an additional option, and current consensus reports emphasize the need for studies evaluating IPC in combination with MLD. Previous studies comparing IPC and MLD, either alone or in combination, have shown inconsistent results. Some reported no significant difference between treatment groups, while others suggested additional benefits of IPC, particularly in reducing limb heaviness and tension. However, there is still insufficient evidence to clarify the exact role of IPC within CDT. The aim of this study is to investigate the acute effects of using IPC instead of MLD, or in combination with MLD, on arm circumference, arm volume, shoulder range of motion, and quality of life in patients with BCRL.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: Complete Decongestive Therapy (CDT) — Manual lymph drainage, multilayer bandaging, skin care, and exercise. 75 minutes per session, 5 sessions per week, for 3 weeks.
  • Procedure: CDT + Intermittent Pneumatic Compression (IPC) — Complete decongestive therapy program including manual lymph drainage, multilayer bandaging, skin care, and exercise, plus intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 115 minutes per session, 5 sessions per week, for 3 weeks.
  • Procedure: CDT without Manual Lymph Drainage plus Intermittent Pneumatic Compression — Complete decongestive therapy consisting of multilayer bandaging, skin care, and exercise, with manual lymph drainage replaced by intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 75 minutes per session, 5 sessions per week, for 3 weeks.

Primary Outcomes

  • Arm volumetric measurements (1 day before rehabilitation and 3 weeks after the start of rehabilitation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-15
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pamukkale University
Principal Investigators:
  • Oya Topuz, Professor (STUDY_DIRECTOR) - Pamukkale University
Contact Information
Study Contact:
Emre Bezmez, M.D.
+905319902220
emrebezmez@gmail.com
Emre Bezmez, M.D.
+905319902220
Pamukkale University
Interventions
  • Procedure: Complete Decongestive Therapy (CDT) — Manual lymph drainage, multilayer bandaging, skin care, and exercise. 75 minutes per session, 5 sessions per week, for 3 weeks.
  • Procedure: CDT + Intermittent Pneumatic Compression (IPC) — Complete decongestive therapy program including manual lymph drainage, multilayer bandaging, skin care, and exercise, plus intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 115 minutes per session, 5 sessions per week, for 3 weeks.
  • Procedure: CDT without Manual Lymph Drainage plus Intermittent Pneumatic Compression — Complete decongestive therapy consisting of multilayer bandaging, skin care, and exercise, with manual lymph drainage replaced by intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 75 minutes per session, 5 sessions per week, for 3 weeks.
Study Locations (1 sites)
Pamukkale University, Denizli, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Female gender * Patients aged 18-65 years * Having a history of unilateral mastectomy and lymph node dissection at least one year ago due to breast cancer diagnosis. * Having unilateral breast cancer-related upper extremity lymphedema (\>20% volume difference between the two upper extremities or \>2 cm difference in circumference at any measured point) according to the diagnostic criteria of the International Society of Lymphology (Committee 2023) for at least six months. * Not having received lymphedema treatment or exercise therapy for the last six months * Completing breast cancer primary treatment at least 6 months ago (except hormone therapy/aromatase inhibitors) Exclusion Criteria: * Bilateral breast cancer * Bilateral axillary lymph node dissection * Metastatic breast cancer * Receiving ongoing radiotherapy or chemotherapy * Primary or bilateral lymphedema * Having active cancer * Presence of stage 3 lymphedema * Uncontrolled serious systemic disease (cardiopulmonary diseases, arterial or venous diseases, renal dysfunction, uncontrolled hypertension or hypotension, cardiac arrhythmia, scleroderma, Sudek's atrophy). * Current or recent (within the last 3 months) infection (cellulitis, lymphangitis) or deep venous thrombosis * Presence of open wounds * Using medications that may affect body fluid and electrolyte balance (diuretics, etc.). * Individuals with serious mental and sensory problems * Being pregnant * Body mass index \>40 kg/m2
Conditions Metabolic Associated Fatty Liver Disease...
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD). The main questions it aims to answer are: 1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD? 2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose tissue? Researchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups. Participants will attend 2 short visits and 1 full-day visit, including: * Body scan (DXA) to check fat and bone composition * MRI to measure liver fat. * Blood tests. * Ultrasound to check liver stiffness and scarring. * Fat biopsies * 8-hour hormone (including glucagon) and tracer infusion * PET-CT scans

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Glugagon — Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers. \[11C\]palmitate PET during low and high dose glucagon.

Primary Outcomes

  • Hepatic FFA oxidation rate (µmol/100Ml/min) (30 minutes at steady-state)
  • Blood and adipose tissue proteomic and lipidomic profiles (30 minutes after steady-state)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-29
Completion: 2028-07-31
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Collaborators: Novo Nordisk A/S
Contact Information
Study Contact:
Kia E. Fonfara, Medical Doctor
+4524607114
kia.eistrup@clin.au.dk
Kia E. Fonfara, Medical Doctor
+4524607114
kia.eistrup@clin.au.dk
Aarhus University Hospital
Interventions
  • Other: Glugagon — Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers. \[11C\]palmitate PET during low and high dose glucagon.
Study Locations (1 sites)
Aarhus University Hospital, Aarhus, 8000 Denmark
Eligibility Criteria
Inclusion Criteria: * BMI \> 26 kg/m² * confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment * steatosis FF% \> 5,6% on MR spectroscopy for MAFLD group Exclusion Criteria: * Alcohol abuse (\>10 units per week for both sexes) or other substance abuse * Smoking * Current or previous malignant disease * Blood donation within the last 3 months prior to the study day * Participation in studies involving radioactive isotopes within the past 3 months * Pregnancy * Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol/mol) * C-peptide \< 200 pmol/L * Previous acute myocardial infarction (AMI) * Clinical symptoms of heart failure * Current or previous malignant disease * Known ongoing systemic disease, except for dyslipidaemia and hypertension * Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions: 1. Participants treated with statins may be included following a 2-week washout period prior to the experimental study day. 2. Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only. 3. Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day.
Conditions Major Depressive Disorder (MDD)
Phase PHASE2
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: SPN-821 2400 mg — SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling
  • Drug: Placebo — Matched placebo oral tablets

Primary Outcomes

  • Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-19
Completion: 2027-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Supernus Pharmaceuticals, Inc.
Contact Information
Study Contact:
Gianpiera Ceresoli-Borroni, PhD
301-838-2521
gceresoliborroni@supernus.com
Interventions
  • Drug: SPN-821 2400 mg — SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling
  • Drug: Placebo — Matched placebo oral tablets
Study Locations (1 sites)
Collaborative Neuroscience Network, Garden Grove, California 92845 United States
Eligibility Criteria
Inclusion Criteria: * Current diagnosis of MDD according to the DSM-5 for either single or recurrent MDE without psychotic features confirmed by the MINI * Duration of current MDE of at least 8 weeks * MADRS total score of ≥ 24 at the Screening Visit and Day 1 Visit * CGI-S score of ≥ 4 (moderately ill or worse) at the Screening Visit and Day 1 Visit * Stable, therapeutic dose of one of the following protocol-approved ADTs as a monotherapy for ≥ 8 weeks before the Screening Visit and ≥ 10 weeks at the Day 1 Visit. Additionally, inadequate response to the current ADT (less than 50% improvement in depressive symptoms) as confirmed by the ATRQ Investigator administered. Exclusion Criteria: * MADRS total score change of ≥ 25% from the Screening Visit to Day 1 Visit * History of treatment resistant depression (TRD) defined as 3 or more failed ADTs of adequate dose (per ATRQ) and duration (at least 8 weeks) for the current MDE * History of alcohol or substance use disorder according to DSM-5 criteria 6 months before the Screening Visit * Evidence of significant risk for suicidal behavior during participation in the study in the Investigator's opinion * Lifetime diagnosis of any psychotic disorder including MDD with psychosis, MDD with mixed features, bipolar I/II disorder, bipolar depression, schizophrenia, posttraumatic stress disorder, autism spectrum disorder, or any personality disorder or intellectual disability that would affect the ability of the participant to enroll in the study * Diagnosis less then 12 months before screening of severe obsessive-compulsive disorder, acute stress disorder, panic disorder, eating disorders, or any other psychiatric condition that has been the primary focus of treatment, or diagnosis of generalized anxiety disorder less then 6 months before screening. * History of cardiovascular, respiratory, gastrointestinal, renal, hepatic, and hematologic disorders, or other medical disorders that could impose undue risk or compromise the study in the Investigator's opinion * Clinically significant abnormal result prior to Day 1 Visit per Investigator's judgment or abnormal renal function. * Requires treatment with a medication or other substance that is prohibited by the protocol.
Conditions Inflammatory Bowel Disease, Depressive D...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Inflammatory bowel disease (IBD) is often comorbid with depressive disorder, and the development and progression of both conditions are closely related to the composition of gut microbiota and metabolites. However, studies investigating their comorbidity using microbiome and metabolomics approaches remain limited. This study aims to investigate the diversity changes in the gut microbiome and metabolome of patients with comorbid IBD and depressive disorder through multi-omics approaches, to identify specific microbial and metabolic signatures associated with the comorbidity of these two conditions, and to provide a molecular basis for elucidating the underlying mechanisms.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: Not applicable- observational study — observational study with no assigned intervention

Primary Outcomes

  • Gut microbiota composition and relative abundance (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-16
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fang Tang
Contact Information
Study Contact:
Fang Dr. Tang, MD, PhD
+86 053189268253
tangfangsdu@gmail.com
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Interventions
  • Other: Not applicable- observational study — observational study with no assigned intervention
Study Locations (1 sites)
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014 China
Eligibility Criteria
Inclusion Criteria: IBD with Depressive Disorder Group: 1. Patients diagnosed with inflammatory bowel disease (ICD-10 codes: K50-K51). 2. History of depressive disorder diagnosis or previous use of antidepressant medications. 3. Age ≥ 18 years. 4. Willingness to participate and provision of written informed consent. IBD without Depressive Disorder Group: 1. Patients diagnosed with inflammatory bowel disease (ICD-10 codes: K50-K51). 2. No history of depressive disorder diagnosis 3. No previous use of antidepressant medications. 4. Age ≥ 18 years. 5. Willingness to participate and provision of written informed consent. Control Group: 1. No history of inflammatory bowel disease, depressive disorder, or use of antidepressant medications. 2. No gastrointestinal symptoms (e.g., diarrhea, constipation, abdominal pain) within the past 3 months, and no history of gastrointestinal diseases. 3. Age ≥ 18 years. 4. Willingness to participate and provision of written informed consent. Exclusion Criteria: 1. Presence of other major chronic diseases or infections (e.g., malignancy, hypertension, diabetes, coronary heart disease). 2. Use of antibiotics or probiotic supplements within the past 6 months. 3. Inability or difficulty in providing biological samples. 4. Missing essential patient information.
Conditions Diabetes in Adolescence, Type 2 Diabetes...
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to pilot test different strategies to address health related social needs (HRSN) experienced by adolescent and young adult patients with type 2 diabetes and their families. The main questions it aims to answer are: * How feasible are the strategies? * How acceptable are the strategies? * How reliably and consistently can the strategies be implemented? Participants will: Attend regularly scheduled diabetes clinic visits. Complete surveys and interviews. Be connected to community resources and organizations to help address HRSN.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Tailored Resources — Participants will be offered resource lists and warm referrals specific to health-related social needs (HRSN) on a screener. Their clinical team will be sent screener results and asked to talk about and address HRSN at the visit without additional guidance. Participants will be offered physical resources related to disclosed HRSN (e.g., food box for food insecurity).
  • Behavioral: Universal Empowerment — Regardless of disclosed health-related social needs (HRSN), participants will be offered resource lists and warm referral links for food, housing, and transportation needs. At clinic visit, all will be offered physical resources and the opportunity to meet with a social worker. In place of screening results, the clinical team will be sent a message requesting that, when seeing the patient in clinic, they use the provided, easily accessible empowering script about HRSN.
  • Behavioral: Text Messages — Participants will receive text messages once per month for 3 months. Messages will state that community-based resources to address health-related social needs (HRSN) are available if needed, with a link to opt-in to resource lists and warm referral links. Messages will include contact information for the study and clinical teams for optional HRSN discussion. Community Health Worker will not be assigned.
  • Behavioral: Community Health Workers (CHW) — Participants will be assigned a trained CHW to support connection with resources to address HRSN.

Primary Outcomes

  • Acceptability of Intervention: Health-Related Social Needs Screener (at baseline clinic visit)
  • Acceptability of Intervention: Tailored Approach to Address Health-Related Social Needs (1-week after baseline; 3 months)
  • Acceptability of Intervention: Universal Empowerment Approach to Address Health-Related Social Needs (at baseline visit; 1-week after baseline; 3 months)
  • Acceptability of Intervention: Text Messages to Address Health-Related Social Needs (3 months)
  • Acceptability of Intervention: Community Health Workers to Address Health-Related Social Needs (3 months)
  • Fidelity of Intervention (1-week after baseline; 3 months; 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-21
Completion: 2028-07
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: true
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Mary Ellen Vajravelu, MD MSHP (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
  • Maya I Ragavan, MD MPH MS (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Mary Ellen Vajravelu, MD MSHP
412-692-6533
maryellen.vajravelu@pitt.edu
Maya I Ragavan, MD MPH MS
maya.ragavan@chp.edu
Mary Ellen Vajravelu, MD MSHP
4126926533
UPMC Children's Hospital of Pittsburgh
Interventions
  • Behavioral: Tailored Resources — Participants will be offered resource lists and warm referrals specific to health-related social needs (HRSN) on a screener. Their clinical team will be sent screener results and asked to talk about and address HRSN at the visit without additional guidance. Participants will be offered physical resources related to disclosed HRSN (e.g., food box for food insecurity).
  • Behavioral: Universal Empowerment — Regardless of disclosed health-related social needs (HRSN), participants will be offered resource lists and warm referral links for food, housing, and transportation needs. At clinic visit, all will be offered physical resources and the opportunity to meet with a social worker. In place of screening results, the clinical team will be sent a message requesting that, when seeing the patient in clinic, they use the provided, easily accessible empowering script about HRSN.
  • Behavioral: Text Messages — Participants will receive text messages once per month for 3 months. Messages will state that community-based resources to address health-related social needs (HRSN) are available if needed, with a link to opt-in to resource lists and warm referral links. Messages will include contact information for the study and clinical teams for optional HRSN discussion. Community Health Worker will not be assigned.
  • Behavioral: Community Health Workers (CHW) — Participants will be assigned a trained CHW to support connection with resources to address HRSN.
Study Locations (1 sites)
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15224 United States
Eligibility Criteria
Adolescent-Caregiver Dyads will be recruited together. Adolescent Inclusion Criteria: * Age 13 to 22 years old * known diagnosis of type 2 diabetes * followed clinically at UPMC Children's Hospital of Pittsburgh * able to provide assent/consent Caregiver Inclusion Criteria: * Adult (18 years or older) identifying as a primary caretaker of an adolescent or young adult with type 2 diabetes * Has an adolescent/young adult who agrees to participate in the study * able to provide consent Exclusion Criteria: * Inability to complete study questionnaires in English
Conditions Advanced Solid Tumor, Melanoma, Breast C...
Phase PHASE1
Enrollment 6
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by Shanghai Rongrui Pharmaceutical Technology Co., Ltd. The main purpose of this open-label, single-arm study is to assess the preliminary effectiveness and safety of VSV-02 when it is given through two routes: directly into a vein (intravenously) and by injection directly into the tumor (intratumorally). Patients will receive the treatment on the first day of each 3-week cycle, for up to 6 cycles. The study will follow a dose-escalation design to find a suitable dose. Treatment may be stopped if the disease progresses, if side effects become intolerable, or if the patient chooses to withdraw, among other reasons. Researchers will closely monitor patients to see if VSV-02 can help control the cancer and to record any side effects that may occur.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: VSV-02 Injection — VSV-02 Injection is an oncolytic virus vaccine based on an attenuated Vesicular Stomatitis Virus (VSV) that is engineered to encode a CD3/PD-L1 bispecific antibody. It is supplied as a sterile solution by Shanghai Rongrui Pharmaceutical Technology Co., Ltd., with a specification of 1 mL per vial and a viral titer of 3.0×10\^10 PFU/mL. The investigational product is administered via two routes: intratumoral (IT) injection followed by intravenous (IV) infusion on Day 1 (D1) of each 21-day treatment cycle. Patients may receive up to 6 cycles of treatment. In this dose-escalation study, participants are enrolled into predefined dose cohorts. The starting dose for the first cohort is 6×10\^10 PFU via intratumoral injection and 6×10\^11 PFU via intravenous infusion.

Primary Outcomes

  • Objective Response Rate (ORR) (From enrollment until the first occurrence of disease progression or the end of treatment, up to 24 months.)
  • Disease Control Rate (DCR) (From enrollment until the first occurrence of disease progression or the end of treatment, up to 24 months.)
  • Duration of Response (DoR) (From the first objective response (CR or PR) until disease progression or death from any cause, assessed up to 36 months.)
  • Progression-Free Survival (PFS) (From enrollment until the first occurrence of disease progression or death from any cause, assessed up to 36 months.)
  • verall Survival (OS) (From enrollment until death from any cause, assessed up to 60 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-09-22
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Xinxiang Medical College
Principal Investigators:
  • LiuZhong Yang, master (PRINCIPAL_INVESTIGATOR) - First Affiliated Hospital of Xinjiang Medical University
Contact Information
Study Contact:
LiuZhong Yang, master
8613639638824
56236053@qq.com
Ping Lu, Ph.D.
13598722864
lupingdoctor@126.com
The First Affiliated Hospital of Xinxiang Medical University
Interventions
  • Biological: VSV-02 Injection — VSV-02 Injection is an oncolytic virus vaccine based on an attenuated Vesicular Stomatitis Virus (VSV) that is engineered to encode a CD3/PD-L1 bispecific antibody. It is supplied as a sterile solution by Shanghai Rongrui Pharmaceutical Technology Co., Ltd., with a specification of 1 mL per vial and a viral titer of 3.0×10\^10 PFU/mL. The investigational product is administered via two routes: intratumoral (IT) injection followed by intravenous (IV) infusion on Day 1 (D1) of each 21-day treatment cycle. Patients may receive up to 6 cycles of treatment. In this dose-escalation study, participants are enrolled into predefined dose cohorts. The starting dose for the first cohort is 6×10\^10 PFU via intratumoral injection and 6×10\^11 PFU via intravenous infusion.
Study Locations (1 sites)
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan China
Eligibility Criteria
Inclusion Criteria: Voluntary signed informed consent. Age ≥ 18 years. Histologically or cytologically confirmed advanced solid tumor (e.g., melanoma, head and neck squamous cell carcinoma, cervical cancer, osteosarcoma, nasopharyngeal carcinoma, breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer). Disease progression after at least two prior lines of standard therapy (including targeted therapy), or for whom no standard therapy exists or is medically unsuitable. At least one measurable lesion per RECIST 1.1 criteria. At least one lesion accessible for intratumoral injection. ECOG performance status of 0-2. Life expectancy ≥ 12 weeks. Adequate organ and bone marrow function. Negative pregnancy test for women of childbearing potential. Agreement to use effective contraception during the study and for at least 6 months after the last dose. Exclusion Criteria: Symptomatic or untreated brain metastases (asymptomatic or stable for ≥3 months after local therapy allowed). Radiotherapy to the target lesion within 2 months. History of other active malignancy within 5 years (with specific exceptions). Lesion intended for injection with a longest diameter \> 100 mm. Participation in another interventional clinical trial within 4 weeks. Prior or planned organ/tissue transplantation. Active HIV, Hepatitis B, Hepatitis C, or Syphilis infection meeting specific criteria. Requirement for concomitant antiviral or therapeutic anticoagulation. Uncontrolled ≥ Grade 3 active infection. Specific washout periods for prior anti-cancer therapies not met. Uncontrolled cardiovascular disease. Active or history of autoimmune disease (with specific exceptions). Requirement for systemic corticosteroids (\>10 mg prednisone equivalent) within 14 days or during the study. Tumors located in high-risk anatomical sites. Administration of live vaccines during the study period. Known hypersensitivity to any component of the study drug or related immunotherapies. History of severe mental illness, substance abuse, or other conditions that may interfere with study compliance. Pregnancy or lactation. Toxicities from previous anti-cancer therapy not recovered to ≤ Grade 1 (except alopecia). Any other condition deemed inappropriate for participation by the investigator.
Conditions Type 2 Diabetes Mellitus (T2DM), Irrever...
Phase NA
Enrollment 106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

there is limited endodontic research on the effects of DM on pulp tissues. Diabetic human and animal histological research have demonstrated decreased wound repair, chronic pulp inflammation and reduced dentin bridge formation. To date, no human clinical trial has examined the impact of diabetes mellitus on teeth with irreversible pulpitis. Due to the paucity of data in the literature, there is a clinical dilemma whether to recommend root canal therapy or vital pulp therapy in diabetic patients with irreversible pulpitis. To the best of our knowledge, no prospective study has evaluated the outcome of complete pulpotomy versus root canal treatment in T2DM patients with irreversible pulpitis. The aim of this study is to compare and evaluate the success rates of pulpotomy and root canal treatment in type 2 diabetes mellitus patients in mature permanent teeth presenting with clinical symptoms of irreversible pulpitis.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: complete pulpotomy — the exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 5 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 5 minutes. After hemostasis, MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using a carrier. This will be followed by application of a layer of light-cure RMGIC and light-curing for 20 sec. The tooth then will be restored using composite resin following etch and rinse technique.
  • Procedure: Root canal treatment — RCT will be performed in single visit. Root canal orifices will be explored using a DG 16 probe. A size 10 or 15 K-file will be passively inserted into the coronal two- thirds of the canal to verify a smooth glide path. Coronal enlargement will be done using Gates-Glidden drills. Working length will be determined with the help of electronic apex locator and will be confirmed radiographically. Canals will be prepared using the crown down technique with NiTi rotary instruments. The master apical file (MAF) size for each canal will be selected to be three sizes larger than the initial apical binding file at the WL. 5ml of 5.25% sodium hypochlorite using a 30-gauge side-vented needle will be used for optimal irrigation after each instrument. After completion of canal instrumentation, the canals will be irrigated with 5.0 ml of 17% ethylene-diamine-tetra acetic acid for 1 minute followed by a final irrigation with 5.0 ml of 5.25% sodium hypochlorite. Canals will be dried with

Primary Outcomes

  • clinical success (12 months)
  • radiographic success (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Postgraduate Institute of Dental Sciences Rohtak
Principal Investigators:
  • Jigyasa Duhan, MDS (PRINCIPAL_INVESTIGATOR) - PGIDS Rohtak
Contact Information
Study Contact:
Jigyasa Duhan, MDS
+91 9896270449
prashitiduhan@rediffmail.com
Anmol Jain
+91 9599724799
drjain.anmol@gmail.com
Jigyasa Duhan, MDS
+91 9896270449
prashitiduhan@rediffmail.com
PGIDS Rohtak
Interventions
  • Procedure: complete pulpotomy — the exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 5 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 5 minutes. After hemostasis, MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using a carrier. This will be followed by application of a layer of light-cure RMGIC and light-curing for 20 sec. The tooth then will be restored using composite resin following etch and rinse technique.
  • Procedure: Root canal treatment — RCT will be performed in single visit. Root canal orifices will be explored using a DG 16 probe. A size 10 or 15 K-file will be passively inserted into the coronal two- thirds of the canal to verify a smooth glide path. Coronal enlargement will be done using Gates-Glidden drills. Working length will be determined with the help of electronic apex locator and will be confirmed radiographically. Canals will be prepared using the crown down technique with NiTi rotary instruments. The master apical file (MAF) size for each canal will be selected to be three sizes larger than the initial apical binding file at the WL. 5ml of 5.25% sodium hypochlorite using a 30-gauge side-vented needle will be used for optimal irrigation after each instrument. After completion of canal instrumentation, the canals will be irrigated with 5.0 ml of 17% ethylene-diamine-tetra acetic acid for 1 minute followed by a final irrigation with 5.0 ml of 5.25% sodium hypochlorite. Canals will be dried with
Study Locations (1 sites)
PGIDS Rohtak, Rohtak, Haryana 124001 India
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes mellitus defined by HbA1c levels 6.5% - 8% OR FPG ≥126 mg/dL OR 2-hour plasma glucose ≥200 mg/dL during an OGTT OR A random plasma glucose of 200 mg/dL or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis * Age between 18 - 70 years. * Permanent mandibular posterior teeth with clinical and radiographic signs and symptoms indicative of irreversible pulpitis (PAI score ≤2) * Tooth showing positive response to pulp sensibility testing with no tenderness on percussion. * BMI\<30 Kg/m2 Exclusion Criteria: * Patients with immunocompromised diseases or chronic kidney disease * Smokers, pregnant and lactating women * Teeth with immature roots or retained deciduous tooth. * Bleeding could not be controlled in ≥5 minutes. * Tooth with signs and symptoms of apical periodontitis. * Teeth with procedural errors, cracks, fractured teeth * Tooth with probing depth more than 4mm. * Positive history of antibiotic use in the past 1 month or requiring antibiotic prophylaxis and/or analgesic usage in past 3 days. * Patients taking drugs that affect bone metabolism such as immune- suppressants, SSRIs, bisphosphonates, hormone replacement therapy
Conditions Metastatic Breast Cancer ( HER2 Negative...
Phase PHASE2
Enrollment 20
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The H3RAKLES trial would allow patients with a progressive metastatic breast cancer to have access to one more line of systemic therapy. Patients included in this trial will have already received at least two lines of chemotherapy (and potentially several lines of endocrine therapy for patients with a HR+ disease). In this setting, few treatments have demonstrated a clinically meaningful benefit, and any additional option is valuable. Furthermore, the pre-clinical and clinical rationale indicate a high probability of clinical benefit, as previously shown in Table 1, with all patients treated with trastuzumab and a TKI targeting HER2 displaying a response. Besides, with several years of hindsight for the combination of lapatinib, trastuzumab and capecitabine, we expect excellent tolerance with the same treatment without capecitabine. The H3RAKLES single-arm phase II trial will evaluate the combination of tucatinib, a HER2 TKI, and trastuzumab, a HER2-directed antibody in patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation. To demonstrate the actionability of ERBB3 mutations, all patients will receive a combination of trastuzumab and tucatinib, in 3-weeks cycles.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tucatinib (ONT-380) — Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
  • Drug: Trastuzumab (Herceptin) — Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination

Primary Outcomes

  • Clinical benefit rate (CBR) (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-31
Completion: 2029-06-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Curie
Collaborators: Pfizer, Eurofins, UNICANCER
Principal Investigators:
  • François-Clément Bidard, Prof. (PRINCIPAL_INVESTIGATOR) - Institut Curie
  • Sandra BIDARD (PRINCIPAL_INVESTIGATOR) - Institut Curie
Contact Information
Study Contact:
Sandra Clinical Project Manager
+33156245944
drci.promotion@curie.fr
Sandra Regulatory Assistant
+33156245765
drci.promotion@curie.fr
Laura POETSCH, MD
Polyclinique Bordeaux Nord Aquitaine
Interventions
  • Drug: Tucatinib (ONT-380) — Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
  • Drug: Trastuzumab (Herceptin) — Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
Study Locations (9 sites)
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33 300 France
Chu Dupuytren- Limoges, Limoges, 87 042 France
Institut Paoli-Calmettes, Marseille, 13009 France
Centre Antoine Lacassagne, Nice, 06 189 France
CHU de Nîmes, Nîmes, 30 029 France
Centre Eugène Marquis, Rennes, 35 042 France
Institut Curie_ Site Saint-Cloud, Saint-Cloud, 92 210 France
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud, Toulouse, 31 059 France
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, 54 519 France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Metastatic or unresectable breast cancer * HER2-negative (defined as having an IHC 0+, IHC 1+, or IHC 2+ and ISH non-amplified, per ASCO/CAP guidelines) on last assessable tumor sample * Having received ≥ 2 previous chemotherapy lines for advanced breast cancer: including at least one line of conjugated antibody, at the investigator's discretion or if a germinal BRCA mutation is present, a PARP inhibitor. * Class IV or V somatic ERBB3 mutation as determined on a tumor sample obtained during the molecular screening step * ECOG performance status ≤ 2 (Appendix A) * Evaluable disease, per RECIST v1.1 inclusion criteria * Left ventricular ejection fraction (LVEF) ≥50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study treatment * Adequate organ function: 1. Creatinine clearance ≥ 50 mL/min as calculated per institutional guidelines 2. Total bilirubin ≤1.5 X upper limit of normal (ULN), except for patients with known Gilbert's disease, who may enroll if the conjugated bilirubin is ≤1.5 X ULN. 3. Transaminases (aspartate aminotransferase and alanine aminotransferase) ≤ 2.5 X ULN (≤ 5 X ULN if the patient has liver metastases) * Women of childbearing potential (WCBP) must have a negative serum pregnancy test \< 7 days prior to first dose of treatment. A woman is considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as the absence of menses for 12 months without an alternative cause. * WCBP (as defined above) and men with partners of childbearing potential must agree to use a highly effective birth control method during the study and for 3 months after completion of investigational treatment. * Patients should be eligible for the treatment step according to the investigator's opinion. * Patients must be covered by a health insurance plan. * Patients able to provide signed informed consent. Exclusion Criteria: * Having received any prior treatment targeting HER2. Prior treatment with trastuzumab deruxtecan is allowed, per label, in patients with HER2-low metastatic breast cancer (IHC 1+ or 2+, ISH non-amplified) * History of allergic reactions to trastuzumab or tucatinib or chemically similar drugs * Patients who are pregnant, breastfeeding, or planning a pregnancy from time of informed consent until 7 months after the final dose of study drug * Inability to swallow pills or having a significant gastro-intestinal disease or a history of surgery which would preclude the adequate oral absorption of medications * Having used a strong CYP2C8 inhibitor within a duration of 5 half-lives prior to the first dose of study treatment, or have used a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment (see Appendix B and Appendix C) * Treatment with any systemic anti-cancer therapy (including hormonal therapy), non-central nervous system (CNS) radiation, or experimental agent ≤ 3 weeks prior to the first dose of study treatment, except gonadotropin releasing hormone (GnRH) agonists * Participation in another interventional clinical trial. * Symptomatic and untreated brain metastases or brain metastases requiring urgent treatment, or brain metastases requiring a dose \> 2 mg of dexamethasone (or equivalent) * Whole brain radiotherapy \< 21 days prior to first dose of treatment, stereotactic radiotherapy \< 7 days prior to first dose of treatment * Leptomeningeal metastases * Major surgery (including surgery of brain metastases) \< 21 days prior to first dose of treatment * Evidence within 2 years of the start of study treatment of another malignancy that required systemic treatment * Have known myocardial infarction or unstable angina within 24 weeks prior to first dose of study treatment * Have clinically significant cardiopulmonary disease such as: * Ventricular arrhythmia requiring therapy, * Uncontrolled hypertension (defined as persistent systolic blood pressure \>150 mmHg and/or diastolic blood pressure \> 100 mm Hg on antihypertensive medications) * Any history of symptomatic congestive heart failure * Severe dyspnea at rest (CTCAE v5.0 Grade 3 or above) due to complications of advanced malignancy * Hypoxia requiring supplementary oxygen therapy except when oxygen therapy is needed only for obstructive sleep apnea * Presence of ≥ Grade 2 QTc prolongation on screening ECG * Conditions potentially resulting in drug-induced prolongation of the QT interval or torsade de pointes: * Congenital or acquired long QT syndrome * Family history of sudden death * History of previous drug-induced QT prolongation * Current use of medications with known and accepted associated risk of QT prolongation (see row "Accepted Association" in Appendix D) * Are known carriers of active Hepatitis B or Hepatitis C or have other known chronic liver disease * Are known to be positive for human immunodeficiency virus (HIV) * Altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent. * Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons * Person deprived of liberty or under guardianship
Conditions Diabetic Kidney Disease (DKD)
Phase PHASE2
Enrollment 195
Locations 58 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: ALN-ANG3 — Administered per the protocol
  • Drug: Evinacumab — No longer being administered
  • Drug: Placebo — Administered per the protocol

Primary Outcomes

  • Percent Change in Urine Albumin to Creatinine Ratio (UACR) (Baseline to Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-09
Completion: 2028-10-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 195 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regeneron Pharmaceuticals
Principal Investigators:
  • Clinical Trial Management (STUDY_DIRECTOR) - Regeneron Pharmaceuticals
Contact Information
Study Contact:
Clinical Trials Administrator
844-734-6643
clinicaltrials@regeneron.com
Interventions
  • Drug: ALN-ANG3 — Administered per the protocol
  • Drug: Evinacumab — No longer being administered
  • Drug: Placebo — Administered per the protocol
Study Locations (58 sites)
Apogee Clinical Research, LLC, Huntsville, Alabama 35801 United States
Applied Research Center of Arkansas, Little Rock, Arkansas 72205 United States
AME Clinical Research, Huntington Beach, California 92647 United States
Amicis Research Center, Northridge, California 91325 United States
FOMAT - Vista del Mar Medical Group, Oxnard, California 93036 United States
Central Coast Nephrology, Salinas, California 93901 United States
North America Research Institute, San Dimas, California 91773 United States
Amicis Research Center, Santa Clarita, California 91355 United States
Valiance Clinical Research, Tarzana, California 91356 United States
Amicis Research Center, Valencia, California 91355 United States
Eligibility Criteria
Key Inclusion Criteria: 1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management 2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening 3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening 4. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening Key Exclusion Criteria: 1. Known medical history or clinical evidence indicative of non-diabetic renal disease 2. Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation 3. Medically unstable as assessed by the investigator or hospitalization (ie, \>24 hours) within 30 days of the screening visit NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply